Across TCGA pan-cancer cohorts, GSTA2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSTA2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GSTA2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, LUAD, and LGG are the cancer types where GSTA2 Mutation most reproducibly stratifies survival.